How should I manage akathisia in a patient who is taking lurasidone?

Management of Lurasidone-Induced Akathisia

If a patient develops akathisia on lurasidone, first reduce the dose or switch to an alternative antipsychotic with lower akathisia risk (such as quetiapine or olanzapine), and if symptoms persist or dose reduction is not feasible, add propranolol 10–30 mg two to three times daily as the most evidence-based pharmacological intervention. 1

Step 1: Confirm the Diagnosis of Akathisia

• Akathisia presents as subjective inner restlessness and an urge to move, accompanied by observable restless movements such as pacing, inability to sit still, or restless legs 2, 3
• The syndrome is often misinterpreted as anxiety, agitation, or worsening psychosis, leading to inappropriate dose escalation rather than recognition of a medication side effect 3
• Even low introductory doses of lurasidone can precipitate severe akathisia, so maintain a high index of suspicion early in treatment 4
• Lurasidone carries a relative risk of akathisia 2.7 times higher than placebo, the highest among newer second-generation antipsychotics 5

Step 2: Dose Reduction as First-Line Intervention

• Reduce the lurasidone dose immediately if clinically feasible, as this is the most direct and effective intervention for drug-induced akathisia 2, 3
• Most akathisia side effects with lurasidone are transitory and can be ameliorated by dose adjustment 6
• If dose reduction adequately controls akathisia without compromising psychiatric stability, maintain the lower dose and monitor closely 6

Step 3: Switch to an Alternative Antipsychotic

• Quetiapine or olanzapine (5–7.5 mg/day) are preferred alternatives due to their significantly lower propensity to cause akathisia compared to lurasidone 1
• Aripiprazole should be avoided as an alternative, as it also carries substantial akathisia risk and may precipitate the same problem 1, 4, 5
• Complete discontinuation of lurasidone typically results in resolution of acute akathisia, as demonstrated in case reports where severe symptoms resolved entirely upon stopping the offending agent 4

Step 4: Pharmacological Management of Persistent Akathisia

First-Line Adjunctive Treatment: Beta-Blockers

• Propranolol 10–30 mg two to three times daily is the most thoroughly studied and effective pharmacological intervention for antipsychotic-induced akathisia 1, 2
• Propranolol can be used alongside lurasidone if switching is not immediately possible or if the patient requires continued antipsychotic treatment 1
• Beta-blockers address the underlying noradrenergic imbalance in the basal ganglia that contributes to akathisia pathophysiology 2

Second-Line Options: Benzodiazepines

• Lorazepam is effective for acute management of akathisia and can provide rapid symptomatic relief while other interventions are being implemented 1, 2
• Benzodiazepines are particularly useful when immediate symptom control is needed, though they should not be used as monotherapy long-term 2

Third-Line Options: Mirtazapine and Gabapentinoids

• Low-dose mirtazapine is a well-studied alternative for akathisia management, particularly when beta-blockers are contraindicated or ineffective 2
• Voltage-gated calcium channel blockers (gabapentin, pregabalin) may be effective in resistant cases 2
• Rotation between different pharmacological strategies may be optimal when akathisia proves resistant to initial interventions 2

Common Pitfalls to Avoid

• Do not misinterpret akathisia as worsening psychosis or anxiety and increase the antipsychotic dose, as this will exacerbate the problem 3
• Do not assume that second-generation antipsychotics like lurasidone are free from extrapyramidal side effects—even drugs with no other motor side effects can induce significant akathisia 2, 5
• Do not rely solely on anticholinergic medications (such as benztropine), as these are less effective for akathisia compared to other extrapyramidal symptoms and are not first-line treatment 2
• Be aware that chronic or tardive akathisia may persist after lurasidone discontinuation and prove resistant to pharmacological treatment, requiring more aggressive management strategies 2

Monitoring and Follow-Up

• Monitor for sedation when using quetiapine or olanzapine as alternative antipsychotics 1
• Reassess akathisia severity regularly using standardized scales to track treatment response 3
• Maintain vigilant clinical monitoring particularly during dose titration or medication switches to prevent patient distress 4